Citigroup Raises Coherus Biosciences (CHRS) Price Target to $25.00

Coherus Biosciences (NASDAQ:CHRS) had its price objective upped by Citigroup from $23.00 to $25.00 in a research note issued to investors on Friday, March 9th. Citigroup currently has a buy rating on the biotechnology company’s stock.

A number of other research firms have also issued reports on CHRS. BidaskClub upgraded Coherus Biosciences from a hold rating to a buy rating in a research note on Saturday, January 13th. Zacks Investment Research lowered Coherus Biosciences from a buy rating to a hold rating in a research note on Tuesday, January 9th. ValuEngine lowered Coherus Biosciences from a sell rating to a strong sell rating in a research note on Friday, November 10th. Finally, Maxim Group restated a buy rating and set a $15.00 price objective (down previously from $20.00) on shares of Coherus Biosciences in a research note on Friday, March 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. The company currently has an average rating of Buy and an average price target of $29.33.

How to Become a New Pot Stock Millionaire

Shares of CHRS stock traded down $0.80 during trading hours on Friday, reaching $10.25. The company had a trading volume of 844,514 shares, compared to its average volume of 805,896. The company has a debt-to-equity ratio of 3.33, a quick ratio of 5.12 and a current ratio of 5.12. Coherus Biosciences has a twelve month low of $8.05 and a twelve month high of $24.70. The firm has a market cap of $664.56, a P/E ratio of -2.29 and a beta of 3.39.

Coherus Biosciences (NASDAQ:CHRS) last posted its earnings results on Thursday, March 8th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.02. equities research analysts predict that Coherus Biosciences will post -3 EPS for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the business. Teacher Retirement System of Texas acquired a new stake in Coherus Biosciences during the 4th quarter valued at approximately $101,000. Ladenburg Thalmann Financial Services Inc. grew its stake in Coherus Biosciences by 497.4% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,600 shares of the biotechnology company’s stock valued at $168,000 after purchasing an additional 10,491 shares in the last quarter. Landscape Capital Management L.L.C. acquired a new stake in Coherus Biosciences during the 4th quarter valued at approximately $116,000. Bank of Montreal Can acquired a new stake in Coherus Biosciences during the 4th quarter valued at approximately $135,000. Finally, Voya Investment Management LLC grew its stake in Coherus Biosciences by 32.2% during the 2nd quarter. Voya Investment Management LLC now owns 17,607 shares of the biotechnology company’s stock valued at $253,000 after purchasing an additional 4,293 shares in the last quarter. Hedge funds and other institutional investors own 82.29% of the company’s stock.

WARNING: This piece of content was reported by Enterprise Leader and is the property of of Enterprise Leader. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://theenterpriseleader.com/2018/04/02/citigroup-boosts-coherus-biosciences-chrs-price-target-to-25-00.html.

Coherus Biosciences Company Profile

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Analyst Recommendations for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply